These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 16413103

  • 1. The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomy.
    Chun FK, Briganti A, Lebeau T, Fradet V, Steuber T, Walz J, Schlomm T, Eichelberg C, Haese A, Erbersdobler A, McCormack M, Perrotte P, Graefen M, Huland H, Karakiewicz PI.
    Eur Urol; 2006 Feb; 49(2):273-8; discussion 278-9. PubMed ID: 16413103
    [Abstract] [Full Text] [Related]

  • 2. Comparative assessment of the 1992 and 2002 pathologic T3 substages for the prediction of biochemical recurrence after radical prostatectomy.
    Steuber T, Erbersdobler A, Graefen M, Haese A, Huland H, Karakiewicz PI.
    Cancer; 2006 Feb 15; 106(4):775-82. PubMed ID: 16400637
    [Abstract] [Full Text] [Related]

  • 3. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L, Jones TD, Lin H, Eble JN, Zeng G, Carr MD, Koch MO.
    J Urol; 2005 Dec 15; 174(6):2181-5. PubMed ID: 16280760
    [Abstract] [Full Text] [Related]

  • 4. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system.
    van Oort IM, Witjes JA, Kok DE, Kiemeney LA, Hulsbergen-Van De Kaa CA.
    BJU Int; 2008 Aug 15; 102(4):438-41. PubMed ID: 18336608
    [Abstract] [Full Text] [Related]

  • 5. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U, Scattoni V, Freschi M, Briganti A, Salonia A, Gallina A, Colombo R, Karakiewicz PI, Rigatti P, Montorsi F.
    Eur Urol; 2008 Jul 15; 54(1):118-25. PubMed ID: 18314255
    [Abstract] [Full Text] [Related]

  • 6. The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer.
    Vis AN, Schröder FH, van der Kwast TH.
    Eur Urol; 2006 Aug 15; 50(2):258-65. PubMed ID: 16413660
    [Abstract] [Full Text] [Related]

  • 7. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
    Shariat SF, Abdel-Aziz KF, Roehrborn CG, Lotan Y.
    Eur Urol; 2006 Feb 15; 49(2):293-302. PubMed ID: 16387412
    [Abstract] [Full Text] [Related]

  • 8. Does the tertiary Gleason pattern influence the PSA progression-free interval after retropubic radical prostatectomy for organ-confined prostate cancer?
    van Oort IM, Schout BM, Kiemeney LA, Hulsbergen CA, Witjes JA.
    Eur Urol; 2005 Oct 15; 48(4):572-6. PubMed ID: 16046051
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Preoperative neural network using combined magnetic resonance imaging variables, prostate specific antigen, and Gleason score to predict prostate cancer recurrence after radical prostatectomy.
    Poulakis V, Witzsch U, de Vries R, Emmerlich V, Meves M, Altmannsberger HM, Becht E.
    Eur Urol; 2004 Nov 15; 46(5):571-8. PubMed ID: 15474265
    [Abstract] [Full Text] [Related]

  • 11. Pathological stage T2 subgroups to predict biochemical recurrence after prostatectomy.
    Kordan Y, Chang SS, Salem S, Cookson MS, Clark PE, Davis R, Herrell SD, Baumgartner R, Phillips S, Smith JA, Barocas DA.
    J Urol; 2009 Nov 15; 182(5):2291-5. PubMed ID: 19758638
    [Abstract] [Full Text] [Related]

  • 12. A nomogram predicting long-term biochemical recurrence after radical prostatectomy.
    Suardi N, Porter CR, Reuther AM, Walz J, Kodama K, Gibbons RP, Correa R, Montorsi F, Graefen M, Huland H, Klein EA, Karakiewicz PI.
    Cancer; 2008 Mar 15; 112(6):1254-63. PubMed ID: 18286530
    [Abstract] [Full Text] [Related]

  • 13. Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b.
    Freedland SJ, Partin AW, Epstein JI, Walsh PC.
    Cancer; 2004 Apr 15; 100(8):1646-9. PubMed ID: 15073852
    [Abstract] [Full Text] [Related]

  • 14. Clinical significance of tumor necrosis factor receptor superfamily member 11b polymorphism in prostate cancer.
    Bao BY, Lin VC, Huang SH, Pao JB, Chang TY, Lu TL, Lan YH, Chen LM, Ting WC, Yang WH, Hsieh CJ, Huang SP.
    Ann Surg Oncol; 2010 Jun 15; 17(6):1675-81. PubMed ID: 20204532
    [Abstract] [Full Text] [Related]

  • 15. Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy.
    Walz J, Chun FK, Klein EA, Reuther A, Graefen M, Huland H, Karakiewicz PI.
    Eur Urol; 2009 Feb 15; 55(2):412-19. PubMed ID: 19027223
    [Abstract] [Full Text] [Related]

  • 16. Is prostate-specific antigen (PSA) density better than the preoperative PSA level in predicting early biochemical recurrence of prostate cancer after radical prostatectomy?
    Jones TD, Koch MO, Bunde PJ, Cheng L.
    BJU Int; 2006 Mar 15; 97(3):480-4. PubMed ID: 16469012
    [Abstract] [Full Text] [Related]

  • 17. The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens.
    Marks RA, Koch MO, Lopez-Beltran A, Montironi R, Juliar BE, Cheng L.
    Hum Pathol; 2007 Aug 15; 38(8):1207-11. PubMed ID: 17490720
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.